We are Galapagos UK, a pioneering biotechnology company, with the ambition of becoming a leading biopharmaceutical company, focused on making a difference to people with inflammatory and fibrotic diseases. With our pioneering spirit we aim to make a lasting, positive contribution to society by delivering breakthrough medicines we have discovered to patients. We believe in ‘we’ not ‘us’ and together with the inflammation healthcare community, we will continue to push the possibilities of our work to tackle chronic disease and improve the lives of patients. Our motto is simple: We discover. We dare. We care.

Tillotts are specialists in gastrointestinal health (GI) with over 30 years’ experience developing and manufacturing treatments for inflammatory bowel disease. Tillotts were the originators of the first modified release mesalazine and now have over 2 million patient years’ experience in the treatment of ulcerative colitis.  With a development pipeline of new and innovative medicines for patients with diseases of the digestive system, Tillotts are passionate about GI.

Tillotts are also passionate about supporting health care professionals who care for GI patients in order to help improve patient care. Tillotts LOGIC Education programme offers training and support, and our annual Richard Driscoll Award encourages best practice sharing and recognises the achievements of IBD nurses.

Tillotts are proud to support and sponsor the IBD Registry and Crohn’s & Colitis UK.

Tillotts are part of the Zeria Group.

Gastrointestinal diseases can be complex, debilitating and life-changing. Recognising this unmet need, Takeda has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programmes for over 25 years. Takeda is leading in areas of gastroenterology such as inflammatory bowel disease and short bowel syndrome.

BHR Pharmaceuticals Limited is a market leader in the provision of Point of Care diagnostics, moving appropriate tests from the lab closer to the patient to better manage and treat people. This helps shorten patient pathways, improves the patient experience, and improves efficiency for consultants, nurses and other healthcare professionals. BHR has challenged the conventions of laboratory medicine by showing that point-of-care diagnostics added to the health care professional’s toolkit saves time, money and improves health. Our point-of-care diagnostics have been carefully chosen to assist in streamlining healthcare delivery and improving patient outcomes. 

We at BHR have just launched the World’s first lab accurate rapid TDM device, the ProciseDx, enabling Gastroenterology teams manage IBD patients in just 2-5 minutes with lab-quality results. ProciseDx offers Therapeutic Drug Monitoring of Infliximab and Adalimumab as well as CRP within minutes from a drop of blood as well as FCP test from a stool collection kit that is very simple and easy to use, is stable for 5 days at room temperature and can be run on the analysers with results within minutes. The ProciseDx is an ideal solution for all Rapid Access Clinics, Infusion clinics as well as Proactive monitoring of IBD patients.

We at Trio Healthcare believe everyone has the right to healthy skin. That's why everything we do is driven by the relentless pursuit of healthy peristomal skin. We invented Sil2 Breathable Silicone Technology™, so that the people who use our stoma care products, and prescribe them, can experience a world free from the daily challenge of red, sore skin.

Our new range of Genii™ skincare solutions is the world’s first silicone stoma range. The range includes Genii™ Ostomy Seals, Genii™ Flange Extenders and Genii™ Ostomy Bag which all use Sil2™ Technology for healthier stoma skin as standard. They have been designed to be virtually ‘invisible’ by incorporating a range of features that make them feel light, comfortable, and barely there.

Visit www.trioostomycare.com or call 0800 531 6280 for more information.

Science has always been at the heart of the Yakult company, since the microbiologist Dr Shirota selected and cultivated Lactobacillus casei Shirota and produced the first bottle of Yakult in Japan in 1935. Continuing this passion for science, today Yakult supports independent research in hospitals, universities and institutes worldwide, including the UK and Ireland. Yakult remains at the forefront of scientific research and education, and is committed to supporting healthcare professionals in enhancing the understanding of the gut microbiota and health.

For more information, visit www.yakult.co.uk/hcp or contact the Science Team at science@yakult.co.uk